Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 26, 2022

SELL
$16.0 - $45.99 $7.42 Million - $21.3 Million
-463,909 Closed
0 $0
Q1 2022

May 06, 2022

BUY
$33.17 - $46.98 $2.67 Million - $3.78 Million
80,537 Added 21.01%
463,909 $20.8 Million
Q4 2021

Feb 09, 2022

SELL
$39.06 - $67.58 $1.96 Million - $3.4 Million
-50,307 Reduced 11.6%
383,372 $16.4 Million
Q3 2021

Nov 08, 2021

SELL
$60.13 - $77.6 $1.04 Million - $1.34 Million
-17,215 Reduced 3.82%
433,679 $28.8 Million
Q2 2021

Aug 11, 2021

SELL
$50.07 - $76.78 $517,122 - $792,983
-10,328 Reduced 2.24%
450,894 $33.1 Million
Q1 2021

May 06, 2021

BUY
$58.92 - $97.33 $11.8 Million - $19.6 Million
200,976 Added 77.23%
461,222 $31.6 Million
Q4 2020

Feb 05, 2021

BUY
$43.6 - $73.05 $11.3 Million - $19 Million
260,246 New
260,246 $17.5 Million

Others Institutions Holding CSTL

About CASTLE BIOSCIENCES INC


  • Ticker CSTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 26,297,000
  • Market Cap $724M
  • Description
  • Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...
More about CSTL
Track This Portfolio

Track Pembroke Management, LTD Portfolio

Follow Pembroke Management, LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pembroke Management, LTD, based on Form 13F filings with the SEC.

News

Stay updated on Pembroke Management, LTD with notifications on news.